Clinical trials: Super-Refractory Status Epilepticus
Super-Refractory Status Epilepticus
An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these…
- Trial name
- NCT02433314
- Testing
- SAGE-547
- Sponsor
- Supernus Pharmaceuticals, Inc.
Super-Refractory Status Epilepticus
A Study With SAGE-547 for Super-Refractory Status Epilepticus
This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).
- Trial name
- NCT02477618
- Testing
- SAGE-547
- Where
- 171 sites in United States, Austria and 14 more
- Volunteers
- 132 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Super-refractory Status Epilepticus
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).
- Trial name
- SRSE (NCT02052739)
- Testing
- SAGE-547
- Where
- 17 sites in United States
- Volunteers
- 25 people
- Sponsor
- Supernus Pharmaceuticals, Inc.